Karen Eliadis has joined Lux Capital as its CFO based in Palo Alto. Eliadis was most recently the Chief Financial Officer of BlueRun Ventures.
PALO ALTO, Calif.–(BUSINESS WIRE)–Lux Capital, a leading venture capital firm, today announced that Karen Eliadis has joined the firm as its Chief Financial Officer (CFO) based in Palo Alto.
Karen was most recently the Chief Financial Officer of BlueRun Ventures, a global venture capital firm with more than $1 billion in assets, based in Menlo Park. She was previously Director of Finance of Sofinnova Ventures, a Menlo Park-based technology and life science venture capital firm. Before joining Sofinnova, Karen was Managing Director, Finance for a private equity firm and held senior finance positions at several large organizations. She is a CPA and began her career at Deloitte. Karen is actively involved in the venture community, leading as chair and board member of VCBC, a 250+ member organization of finance professionals in venture capital, and serving on several committees of the NVCA CFO Task Force. In July, Karen will join the board of the West Coast Chapter of the Private Equity CFO Association.
“We’re proud to add Karen to the Lux team,” said Peter Hebert, Co-founder and Managing Partner of Lux Capital. “She’s established herself as a leader in the venture capital finance community and her acumen and insights will be integral to Lux’s continued expansion.”
“Having been intimately involved in the venture industry for more than a decade, I have great admiration for the unique franchise Lux Capital has built,” said Eliadis. “I’m very excited to join at an obvious inflection point in the firm’s growth.”
About Lux Capital
Lux Capital is a leading venture firm focused on founding, seed and early stage investments in emerging technologies. Lux takes an active role in helping entrepreneurs build successful businesses in Energy, Life Sciences and Technology. The Lux investment team has founded more than 20 companies from scratch, including Caliper, Genocea, Illumina, Kala, Kurion, Lux Research, Nanosys, Neurocrine Biosciences, and Vertex Pharmaceuticals. For more information please visit www.luxcapital.com.